Helius Medical Technologies Inc expected to post a loss of $3.77 a share - Earnings Preview

Solana Co

26/03/2024 20:46

* Helius Medical Technologies Inc  HSDT.OQ   HSDT.O  is
expected
to show a fall in quarterly revenue when it reports  results on
March 28 for the period ending December 31 2023
    * The Newtown Pennsylvania-based  company is expected to
report a
12.6% decrease in revenue to $246.33 thousand from $282 thousand
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Helius Medical
Technologies
Inc is for a loss of $3.77 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Helius
Medical
Technologies Inc is $20.00​, above​ its last closing price
of $5.69. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023              -6.00      -5.49     Beat    8.5
 Jun. 30 2023  -6.00       -5.83      -3.00     Beat    48.6
 Mar. 31 2023  -5.48       -5.50      -4.50     Beat    18.2​
 Dec. 31 2022  -6.64       -6.50      -8.50     Missed  -30.8
 ​​Sep.        -10.52      -10.50     -1.50     Beat    85.7
 30 2022                                                
 Jun. 30 2022  -56.00      -56.00     -48.50    Beat    13.4​
 Mar. 31 2022  -56.50      -56.50     -57.50    Missed  -1.8
 Dec. 31 2021  -58.00      -58.00     -65.50    Missed  -12.9
 This summary was machine generated March 26 at 20:46 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)